Clinically isolated syndrome
5 original drugsClinically isolated syndrome has 5 FDA-approved novel treatments, led by Novartis across 8 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Clinically isolated syndrome Market Leaders
Companies with the most FDA-approved novel Clinically isolated syndrome drugs.
Clinically isolated syndrome Treatments by Mechanism
Top 2 mechanisms across 3 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinically isolated syndrome Clinical Pipeline by Phase
6 industry-sponsored trials across 4 sponsors
Novel Clinically isolated syndrome Drugs by Company (New molecular entities)
5 companies have an FDA-approved novel drug for Clinically isolated syndrome.
Reformulations (5 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Clinically isolated syndrome Drug Targets
Molecular targets of approved and investigational Clinically isolated syndrome drugs — 8 targets tracked.
Generic Drugs (4 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs